Reference
Millham LRI, et al. Clinical and Economic Impact of Ibalizumab for People With Multidrug-Resistant HIV in the United States. JAIDS 83: 148-156, No. 2, Feb 2020. Available from: URL: http://doi.org/10.1097/QAI.0000000000002241
Rights and permissions
About this article
Cite this article
Ibalizumab not cost effective for drug-resistant HIV in USA. PharmacoEcon Outcomes News 845, 13 (2020). https://doi.org/10.1007/s40274-020-6516-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6516-z